Neuland Laboratories Limited Financial Ratios
NEULANDLAB · Healthcare · Current price ₹20,135
P/E ratio
71.0x
P/B ratio
16.3x
ROE
19.4%
ROCE
23.6%
Debt / Equity
0.16
Dividend yield
0.1%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 71.0x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 16.3x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 19.4% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 23.6% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.16 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Neuland Laboratories Limited's latest numbers.
Neuland Laboratories Limited profitability
Neuland Laboratories Limited generates a return on equity of 19.4% and a return on capital employed of 23.6%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.16 and a P/E of 71.0x, Neuland Laboratories Limited is conservatively financed. Our overall business-quality score for the company is 6.3 / 10.
Understand the ratios
More on Neuland Laboratories Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.